ClinicalTrials.gg
Not yet recruitingNCT07751588Updated Aug 7, 2026

Plasma ctDNA Monitoring in Pediatric Acute Leukemia

An observational study in Acute Myeloid Leukemia and Acute Lymphoblastic Leukemia, sponsored by Institute of Hematology & Blood Diseases Hospital, China. Not yet recruiting at 1 site in China. Open to participants aged 3 Years to 18 Years. Per ClinicalTrials.gov, last updated 2026-08-07.

Sponsored by Institute of Hematology & Blood Diseases Hospital, China · Observational

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
25
Ages
3 Years to 18 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China — 29 open to participants now, 32 under way, 5 of them phase 3. Leukemia, Myeloid, Acute · Institute of Hematology & Blood Diseases Hospital, China.

Started
2026
with 9 others
Observational
5 of 46
3 open now
Primary completion
2027-06
later than 9 of 31 live
Registered
42nd of 46
by date

Among the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China, this one is one of 10 that started in 2026, is one of 5 observational ones, reaches primary completion later than 9 of the 31 other live ones, and was the 42nd registered.

Leukemia, Myeloid, Acute

3,672 studies on the registry are indexed under Leukemia, Myeloid, Acute; 812 are open to participants now.

Browse Leukemia, Myeloid, Acute studies →

Open to participants now

29 of the 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China are open now, in 1 country. Recruiting first, the newest first:

24 more — sign in →

By country, each count listing its studies:

All 29 open studies →

Where they have run

Who these studies take

Of the 617 Leukemia, Myeloid, Acute studies recruiting now, 359 (58%) set no upper age limit and 219 (35%) stop at 75 or younger; 144 take children under 18; 29 take healthy volunteers.

This study: 3 Years to 18 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Leukemia, Myeloid, Acute by Institute of Hematology & Blood Diseases Hospital, China, or all of them as a file.
02

Study summary

This retrospective-prospective observational cohort study aims to evaluate peripheral blood plasma circulating tumor DNA (ctDNA) dynamics in pediatric acute leukemia and compare ctDNA results with concurrent bone marrow multiparameter flow cytometry minimal residual disease (MFC-MRD), droplet digital PCR (ddPCR), and RNA sequencing findings. The study includes a retrospective cohort with available clinical and molecular data and a prospective cohort with serially collected peripheral blood and bone marrow samples at predefined treatment time points. The study will assess consistence between plasma ctDNA and conventional bone marrow-based assays, characterize longitudinal ctDNA dynamics, and explore the association between ctDNA patterns and relapse or survival outcomes.

Read the detailed description

Minimal residual disease assessment is essential for treatment response evaluation and risk stratification in pediatric acute leukemia. Conventional MRD monitoring mainly relies on bone marrow-based assays, including multiparameter flow cytometry, molecular assays, and sequencing-based methods. However, repeated bone marrow sampling is invasive, and peripheral blood plasma ctDNA may provide a minimally invasive approach for dynamic disease monitoring.

This study will include pediatric patients with acute leukemia who have available peripheral blood plasma ctDNA testing data and corresponding clinical or molecular information. Existing clinical records, laboratory results, leukemia-related genetic findings, bone marrow MFC-MRD results, ddPCR results, RNA sequencing results, treatment information, and follow-up outcomes will be retrospectively collected. After study registration, follow-up outcomes and additional serial molecular monitoring data will be prospectively collected when available.

Peripheral blood plasma cfDNA/ctDNA results will be compared with matched or corresponding bone marrow-based assessments, including MFC-MRD, ddPCR, and RNA sequencing. The study will evaluate the concordance between plasma ctDNA and conventional bone marrow-based assays at different treatment time points, including diagnosis, pre-transplantation, post-transplantation, follow-up, and suspected relapse when available.

The study will further assess ctDNA clearance, persistence, or re-emergence during treatment and follow-up. Exploratory analyses will evaluate whether ctDNA dynamics are associated with treatment response, relapse, event-free survival, relapse-free survival, and overall survival.

03

Conditions studied

  • Acute Myeloid Leukemia
  • Acute Lymphoblastic Leukemia
04

Who can participate

Ages eligible
3 Years to 18 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Children were diagnosised with ALL.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients diagnosed with pediatric acute leukemia, including acute lymphoblastic leukemia, acute myeloid leukemia, or mixed phenotype acute leukemia.
  2. Age younger than 18 years at diagnosis.
  3. Availability of peripheral blood plasma cfDNA/ctDNA testing data.
  4. Availability of clinical data and at least one corresponding bone marrow-based assessment, including MFC-MRD, ddPCR, RNA sequencing.
  5. For prospectively collected follow-up data or samples, written will be obtained from parents or legal guardians.
  6. For retrospectively collected data, consent procedures will follow the approval of the institutional ethics committee.

Exclusion criteria

Exclusion Criteria:

  1. Patients without available peripheral blood plasma cfDNA/ctDNA data.
  2. Patients with insufficient clinical or laboratory data for analysis.
  3. Samples failing cfDNA/ctDNA quality control.
  4. Withdrawal of consent for prospective follow-up or additional sample collection.
  5. Patients judged by the investigator to be unsuitable for inclusion.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
25 participants (estimated)
Patient registry
No
Biospecimen retention
Samples with dna
06

What researchers measure

Primary outcomes

  1. Consistence between peripheral blood plasma ctDNA and bone marrow MFC-MRD

    Concordance between peripheral blood plasma ctDNA status and matched bone marrow MFC-MRD results.

    Time frame: From the date of enrollment to 6 months after hematopoietic stem cell transplantation, assessed up to 6 months post-transplantation.

Secondary outcomes

  1. Event-free survival

    Time frame: The time from diagnosis to relapse, death from any cause, or last follow-up, whichever occurs first, assessed up to 36 months.

  2. Overall survival

    Time frame: From the date of diagnosis until the date of death from any cause or last follow-up, whichever occurs first, assessed up to 36 months.

  3. ctDNA clearance rate

    The rate of change of ctDNA positive to negative after stem cell transplantation.

    Time frame: From the date of enrollment to 6 months after hematopoietic stem cell transplantation, assessed up to 6 months post-transplantation.

07

Study locations

1 site
  • Department of Pediatric Hematology/Oncology,Institute of Hematology and Blood Disease Hospital, Chinese Academy of Medical Sciences
    Tianjin, Tianjin Municipality 300020, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Start is estimated for Jul 2026; primary completion for Jun 2027, 11 months later.

Of 128 non-industry observational studies under Leukemia, Myeloid, Acute, half reached primary completion within 66 months of starting (the median), counting those still running; a quarter within 40 and three quarters within 234. This study's planned 11 months is below that.

Counting every sponsor, half of 160 studies reached it within 54 months; a quarter within 35 and three quarters within 154.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 21, 2026
First posted
Aug 7, 2026
StartEst.
Jul 11, 2026
Primary completionEst.
Jun 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Aug 7, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 7, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07751588
Responsible party
Sponsor
First posted
Aug 7, 2026
Start date
Jul 11, 2026 (estimated)
Primary completion
Jun 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Aug 7, 2026

Study contacts

Lipeng Liu, MD
Contact
liulipeng@ihcams.ac.cn
86-22-23909336
Xiaofan Zhu, MD
principal investigator · Institute of Hematology and Blood Diseases Hospital, CAMS & PUMC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion